Leqvio Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The leqvio market research report is one of a series of new reports that provides leqvio market statistics, including the leqvio industry global market size, regional shares, competitors with the leqvio market share, detailed leqvio market segments, market trends, and opportunities, and any further data you may need to thrive in the leqvio industry. This leqvio market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to the rising prevalence of cardiovascular diseases globally, growing awareness about the high efficacy of PCSK9 inhibitors, increasing cases of high cholesterol, growth in the geriatric population, and growth of biologic drugs. Major trends in the forecast period include a growing demand for advanced hypercholesterolemia treatments, expanding indications through ongoing research, continuous approvals from regulatory bodies like the FDA, advancements in biopharmaceutical research, and advancements in drug development.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the leqvio market. Cardiovascular diseases encompass a range of conditions affecting the heart and blood vessels, often leading to heart attacks, strokes, and high blood pressure. Factors contributing to the development of these diseases include poor diet, physical inactivity, excessive alcohol consumption, diabetes, and age. Leqvio works by blocking the PCSK9 protein, which enhances the liver's ability to remove LDL cholesterol from the bloodstream. This reduces LDL cholesterol levels, thereby lowering the risk of heart attacks, strokes, and other cardiovascular events. For instance, in September 2024, the British Heart Foundation reported that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, with 4 million males and 3.6 million females living with these conditions. These diseases account for around 27% of all deaths in the UK, leading to over 170,000 deaths annually, or roughly 480 deaths per day, equivalent to one death every three minutes. This rising prevalence of cardiovascular diseases is a key factor in the growth of the leqvio market.

The growth of the geriatric population is also expected to boost the demand for leqvio. The geriatric population, typically defined as individuals aged 65 and older, has been expanding due to advancements in healthcare and medical technology, which have significantly increased life expectancy. Leqvio helps lower LDL cholesterol, simplifying medication management for older adults. Its long-lasting effects reduce cardiovascular risks, improving health outcomes for the elderly. For example, in January 2024, the Population Reference Bureau reported that the U.S. population aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, marking a 47% increase. This age group's share of the total population is projected to rise from 17% to 23% over the same period. As a result, the growing geriatric population is driving the expansion of the leqvio market.

A significant trend in the leqvio market involves the development of long-acting injectable therapies to better manage high cholesterol and cardiovascular risks. Injectable prescription medicines are administered at regular intervals to ensure sustained therapeutic effects. In July 2023, Novartis, a Switzerland-based pharmaceutical company, received FDA approval for a label update for Leqvio (inclisiran). The update allows its use earlier for patients with elevated LDL cholesterol and an increased risk of heart disease, in addition to diet and statin therapy. With two doses per year after an initial two doses, Leqvio can reduce LDL cholesterol by up to 52%, offering a solution for patients who struggle to reach their LDL target despite statin therapy. The label update highlights the robust safety and efficacy data from the VictORION clinical trial program.

The key company operating in leqvio market is Novartis AG.

North America was the largest region in the leqvio market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in leqvio report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Leqvio market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Leqvio is an siRNA-based therapy designed to lower low-density lipoprotein (LDL) cholesterol by silencing the mRNA responsible for the production of PCSK9 in the liver. This process enhances the liver’s ability to clear LDL-C from the bloodstream, reducing the risk of heart attacks, strokes, and other cardiovascular events in patients at high risk.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of leqvio formulations are subcutaneous injectable forms, available in pre-filled syringes or auto-injectors. The subcutaneous injectable formulation is administered in a healthcare setting, delivering a controlled, long-acting dose typically every six months following the initial dose. It is used for various indications, including the treatment of hyperlipidemia, management of atherosclerotic cardiovascular disease (ASCVD), and treatment of familial hypercholesterolemia. Leqvio is suitable for different patient demographics, including adults, geriatric patients, and those with comorbid conditions. It is distributed through multiple channels, such as direct sales, wholesalers, distributors, retail pharmacies, and online pharmacies, and is used by various end users, including hospitals, cardiovascular clinics, specialty pharmacies, and home healthcare providers.

The leqvio market consists of sales of multi-dose vials and ready-to-use liquid vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.